Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032505718> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3032505718 endingPage "318" @default.
- W3032505718 startingPage "314" @default.
- W3032505718 abstract "ObjectiveTo assess the efficacy of low-dose etoposide in patients with adult-onset Still disease (AOSD) refractory to conventional treatment.MethodsThis was a retrospective study of etoposid treat-ment in 24 patients with conventional treatment-refractory AOSD. Mann-Whitney U-test, Student's t test and chi-squared test were used for analysis.ResultsThe age of the patients was (38±13) years. The median dur-ation of AOSD before etoposide initiation was 2.5 months [interquartile range (IQR)] 1 month to 14 years). The median dosageof etoposide was 575 mg (IQR 150-1 400 mg). The median treatment course was 4 weeks (IQR 2 weeks to 10 months). Etoposide treatment resulted in rapid and maintained improvement in both clinical and laboratory parameters. The median dosage of methylprednisolone was also reduced. The most common side effectwas infection, and other side effects were mild leukopenia or neutropenia, gastrointestinal effects and hair loss. Two patients died and 22 patients survived. With an average follow-up of 14 months (IQR 1-32 months), 4 of which were treated with corticosteroid alone, and 18 patients were treated with corticosteroid plus immunosuppressive agents. The patient's condition was stable without disease flare.ConclusionEtopo-side treatment is associated with rapid and maintained clinical and laboratory improvement in patients with refractory AOSD. Infection is the most common side effect. It is necessary to carry out large samples and long-term follow-up clinical studies to evaluate its exact effect and safety.Key words: Still's disease, adult-onset; Lymphocytosis; Histiocytosis, non-Langenhans cells; Etoposide" @default.
- W3032505718 created "2020-06-05" @default.
- W3032505718 creator A5000917514 @default.
- W3032505718 creator A5039687656 @default.
- W3032505718 creator A5061817335 @default.
- W3032505718 date "2018-05-15" @default.
- W3032505718 modified "2023-09-27" @default.
- W3032505718 title "Low dose efficacy of etoposide on conventional treatment-refractory adult-onset Still disease" @default.
- W3032505718 doi "https://doi.org/10.3760/cma.j.issn.1007-7480.2018.05.006" @default.
- W3032505718 hasPublicationYear "2018" @default.
- W3032505718 type Work @default.
- W3032505718 sameAs 3032505718 @default.
- W3032505718 citedByCount "0" @default.
- W3032505718 crossrefType "journal-article" @default.
- W3032505718 hasAuthorship W3032505718A5000917514 @default.
- W3032505718 hasAuthorship W3032505718A5039687656 @default.
- W3032505718 hasAuthorship W3032505718A5061817335 @default.
- W3032505718 hasConcept C119060515 @default.
- W3032505718 hasConcept C121332964 @default.
- W3032505718 hasConcept C126322002 @default.
- W3032505718 hasConcept C141071460 @default.
- W3032505718 hasConcept C142424586 @default.
- W3032505718 hasConcept C199360897 @default.
- W3032505718 hasConcept C2776694085 @default.
- W3032505718 hasConcept C2777063308 @default.
- W3032505718 hasConcept C2778119113 @default.
- W3032505718 hasConcept C2780873365 @default.
- W3032505718 hasConcept C3454156 @default.
- W3032505718 hasConcept C41008148 @default.
- W3032505718 hasConcept C71924100 @default.
- W3032505718 hasConcept C87355193 @default.
- W3032505718 hasConcept C90924648 @default.
- W3032505718 hasConceptScore W3032505718C119060515 @default.
- W3032505718 hasConceptScore W3032505718C121332964 @default.
- W3032505718 hasConceptScore W3032505718C126322002 @default.
- W3032505718 hasConceptScore W3032505718C141071460 @default.
- W3032505718 hasConceptScore W3032505718C142424586 @default.
- W3032505718 hasConceptScore W3032505718C199360897 @default.
- W3032505718 hasConceptScore W3032505718C2776694085 @default.
- W3032505718 hasConceptScore W3032505718C2777063308 @default.
- W3032505718 hasConceptScore W3032505718C2778119113 @default.
- W3032505718 hasConceptScore W3032505718C2780873365 @default.
- W3032505718 hasConceptScore W3032505718C3454156 @default.
- W3032505718 hasConceptScore W3032505718C41008148 @default.
- W3032505718 hasConceptScore W3032505718C71924100 @default.
- W3032505718 hasConceptScore W3032505718C87355193 @default.
- W3032505718 hasConceptScore W3032505718C90924648 @default.
- W3032505718 hasIssue "5" @default.
- W3032505718 hasLocation W30325057181 @default.
- W3032505718 hasOpenAccess W3032505718 @default.
- W3032505718 hasPrimaryLocation W30325057181 @default.
- W3032505718 hasRelatedWork W1846311518 @default.
- W3032505718 hasRelatedWork W1995369472 @default.
- W3032505718 hasRelatedWork W2074575976 @default.
- W3032505718 hasRelatedWork W2077753080 @default.
- W3032505718 hasRelatedWork W2312334040 @default.
- W3032505718 hasRelatedWork W2409107116 @default.
- W3032505718 hasRelatedWork W2478115498 @default.
- W3032505718 hasRelatedWork W2530019263 @default.
- W3032505718 hasRelatedWork W2548966700 @default.
- W3032505718 hasRelatedWork W2549078280 @default.
- W3032505718 hasRelatedWork W2552824497 @default.
- W3032505718 hasRelatedWork W2561337373 @default.
- W3032505718 hasRelatedWork W2567294264 @default.
- W3032505718 hasRelatedWork W2580676061 @default.
- W3032505718 hasRelatedWork W2589794500 @default.
- W3032505718 hasRelatedWork W27700041 @default.
- W3032505718 hasRelatedWork W2979913721 @default.
- W3032505718 hasRelatedWork W2981063506 @default.
- W3032505718 hasRelatedWork W3031147360 @default.
- W3032505718 hasRelatedWork W3032530922 @default.
- W3032505718 hasVolume "22" @default.
- W3032505718 isParatext "false" @default.
- W3032505718 isRetracted "false" @default.
- W3032505718 magId "3032505718" @default.
- W3032505718 workType "article" @default.